1. Somatostatin receptor expression in parathyroid neoplasms
- Author
-
Eeva Ryhänen, Johanna Louhimo, Caj Haglund, Johanna Arola, Helena Leijon, Sara Storvall, Camilla Schalin-Jäntti, Endokrinologian yksikkö, Department of Medicine, Clinicum, HUS Abdominal Center, University of Helsinki, HUSLAB, Department of Pathology, Department of Surgery, II kirurgian klinikka, and University Management
- Subjects
tumor ,CARCINOMA ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,somatostatin ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,SUBTYPES ,hyperparathyroidism ,03 medical and health sciences ,PROGNOSTIC-FACTORS ,0302 clinical medicine ,Endocrinology ,OCTREOTIDE ,Internal Medicine ,medicine ,Somatostatin receptor 2 ,parathyroid ,Somatostatin receptor 1 ,education ,education.field_of_study ,Hyperparathyroidism ,lcsh:RC648-665 ,Somatostatin receptor-5 ,REASSESSMENT ,Somatostatin receptor ,business.industry ,Parathyroid neoplasm ,Research ,medicine.disease ,CANCER ,TUMORS ,TRANSLOCATION ,3. Good health ,Parathyroid carcinoma ,3121 General medicine, internal medicine and other clinical medicine ,030220 oncology & carcinogenesis ,immunohistochemistry ,Cancer research ,business ,hormones, hormone substitutes, and hormone antagonists ,Primary hyperparathyroidism - Abstract
Introduction Parathyroid carcinoma represents a rare cause of primary hyperparathyroidism. Distinguishing carcinoma from the benign tumors underlying primary hyperparathyroidism remains challenging. The diagnostic criteria for parathyroid carcinoma are local and/or metastatic spreading. Atypical parathyroid adenomas share other histological features with carcinomas but lack invasive growth. Somatostatin receptors are commonly expressed in different neuroendocrine tumors, but whether this also holds for parathyroid tumors remains unknown. Aim Our aim is to examine the immunohistochemical expression of somatostatin receptor 1–5 in parathyroid typical adenomas, atypical adenomas and carcinomas. Methods We used a tissue microarray construct from a nationwide cohort of parathyroid carcinomas (n = 32), age- and gender-matched typical parathyroid adenomas (n = 72) and atypical parathyroid adenomas (n = 27) for immunohistochemistry of somatostatin receptor subtypes 1–5. We separately assessed cytoplasmic, membrane and nuclear expression and also investigated the associations with histological, biochemical and clinical characteristics. Results All parathyroid tumor subgroups expressed somatostatin receptors, although membrane expression appeared negligible. Except for somatostatin receptor 1, expression patterns differed between the three tumor types. Adenomas exhibited the weakest and carcinomas the strongest expression of somatostatin receptor 2, 3, 4 and 5. We observed the largest difference for cytoplasmic somatostatin receptor 5 expression. Conclusions Parathyroid adenomas, atypical adenomas and carcinomas all express somatostatin receptor subtypes 1–5. Somatostatin receptor 5 may serve as a potential tumor marker for malignancy. Studies exploring the role of somatostatin receptor imaging and receptor-specific therapies in patients with parathyroid carcinomas are needed.
- Published
- 2019